Aalberts: highlights ING Benelux Conference Brussels 2024, Ackermans & Van Haaren: Highlights ING Benelux Conference Brussels,Ackermans & Van Haaren: Strong operational performance of underlying companies and guidance fine-tuned upwards, AMG: Highlights ING Benelux Conference Brussels, Aperam: Highlights ING Benelux Conference Brussels, Arcadis: Highlights ING Benelux conference, Azelis: Highlights ING Benelux Conference Brussels, Bekaert: Guidance cut and €200m buyback as sweetener, CFE: No new...
A director at Euronext N.V. sold after exercising options 431 shares at 102.210EUR and the significance rating of the trade was 24/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Onward announces a new grant from the EIC for € 6m over 5-years (of which Onward receives almost € 2m) to assess ARC-BCI in stroke patients. The grant underlines the platform potential of Onward's technologies. We continue to look out to FDA approval for Onward's first product ARC-EX, expected by YE24. We reiterate our € 9.1 TP and Buy rating.
ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore Movement after Stroke Grant supports the first clinical trials studying the potential for brain-computer interface (BCI) and artificial intelligence (AI) technology to restore thought-driven movement after stroke Funding also supports technology development of ARC-BCI System and ARC-IM Lead Approximately 15 million people worldwide experience a stroke each year EINDHOVEN, the Netherlands, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company ...
ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to-Date Highlights Company to provide update on significant milestones and near-term plans, including its recent successful financing and agreements with Ottobock and CEA EINDHOVEN, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will host a webcast to discuss its Q3 2024 business high...
>Conclusion - ENX aims to accelerate organic revenue growth to >5% CAGR from 2023 to 2027, while maintaining high profitability and enhancing innovation and integration. Management is confident in surpassing the lower bound of its targets, and the company will continue to underpromise and over-deliver. ENX will remain razor focused on capital creation and shareholder returns. The new capital allocation policy has been improved by adding another layer of flexibility (i...
Euronext announces volumes for October 2024 Euronext announces volumes for October 2024 Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 8 November 2024 – Euronext today announced trading volumes for October 2024. Monthly and historical volume tables are available at this address: CONTACTS ANALYSTS & INVESTORS – Investor Relations Aurélie Cohen 17 Judith Stein 97 MEDIA – Europe Aurélie Cohen 45 Andrea Monzani 13 Belgium M...
Aperam: 3Q24 results solid, reassuring 4Q24 guidance. bpost: 3Q24 results and FY24 outlook in line. Eurocommercial Properties: Solid results, guidance confirmed at the top of the range. Euronext: A €300m buyback is next. IMCD: In line 3Q24. SBM Offshore: Prosperity taken out. Sif Group: Line 2 now also reporting for duty
>Q3 results bang in-line on revenue, however material beat to the bottom line - ENX came out with Q3 results which were bang in-line with consensus forecast on revenue (€ 396.3m), however 8.1% ahead of net profits (€ 159.5m) which is strong. The company also announced € 300m in buybacks (12 months program). Revenue grew 10% YoY driven by a strong pick-up in the volume business (i.e. trading). On balance, the revenue mix has positives and negatives, with positives stem...
Euronext publishes Q3 2024 results Euronext publishes Q3 2024 results In Q3 2024, Euronext delivered a strong performance, driven by a diversified business model, the successful expansion of Euronext Clearing and continued cost discipline. Euronext reached its “Growth for Impact 2024” strategic plan targets one full quarter in advance. Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 7 November 2024 – Euronext, the leading pan-European market infrastructure, today publishes its results for the third quarter 2024. Q3 2024 revenue and income was up +10.0% at €396.3 million: Str...
Euronext announces its new strategic plan, “Innovate for Growth 2027” Euronext announces its new strategic plan, “Innovate for Growth 2027” “Innovate for Growth 2027” targets the acceleration of Euronext’s revenue growth through innovation and diversification Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 7 November 2024 – Euronext, the leading European capital market infrastructure, today released its new three-year strategic plan, “Innovate for Growth 2027”. “Innovate for Growth 2027” sets out the Group’s ambition to leverage Euronext’s presence on the entire capital ...
Euronext announces launch of a share repurchase programme of €300 million Euronext announces launch of a share repurchase programme of €300 million Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 7 November 2024 – Euronext today announces a share repurchase programme (the ‘Programme’) for a maximum amount of €300 million. This Programme is enabled by Euronext’s strong cash generation capabilities and demonstrates Euronext’s rigorous capital allocation strategy. The Programme will not change the deleveraging path of Euronext, nor its credit rating. The Programme will also be...
Aalberts: Building already bottoming, industry tough. Air France-KLM: Nobody helps. Alfen: Covenant agreement, hikes output Smart Grid. AMG: Sweet for 2024F, sour for 2025F. ArcelorMittal: 3Q24 EBITDA beats by 6%, FCF solid. BAM: 3Q beats, on its way to reach FY guidance. CMB.TECH: 3Q and FY24 reasonable but then more challenges. D'Ieteren: EGM and dividend dates announced; Belron US peer Boyd disappointing 3Q24. GBL: Double-digit TSR expected over 2024-27F. KBC: 3Q better acro...
With 2 changes in our Dynamic Top Pick list (we add Azelis and we remove Solvay) we maintain a defensive stance on the market for 2H24. The long anticipated interest rate cuts by central banks have finally started. The Trump election victory in the US does not bode well for European stocks as he favours a protectionist course. Although industrial companies with a US base could actually benefit. Cleantech names with exposure to the US could also suffer (unless owned by E.Musk). We expect the US ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.